Chapter 7 Archives • Children's Health Defense

1

“Who Needs a Flu Vaccine?,” Centers for Disease Control and Prevention, updated September 13, 2022.

2

“Influenza (Flu) Vaccine and Pregnancy,” Centers for Disease Control and Prevention, updated December 12, 2019.

3

US Food and Drug Administration, AFLURIA® QUADRIVALENT: Package Insert, STN BL 125254 (Summit, NJ: Seqirus USA Inc., 2016).

4

US Food and Drug Administration, AFLURIA® QUADRIVALENT: Package Insert, STN BL 125254 (Summit, NJ: Seqirus USA Inc., 2016).

5

US Food and Drug Administration, Influenza A (H1N1) 2009 Monovalent Vaccine: Package Insert, US License 1739 (Research Triangle Park, NC: GlaxoSmithKline, updated January 2010).

6

Elizabeth Miller et al., “Risk of Narcolepsy in Children and Young People Receiving AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine: Retrospective Analysis,” BMJ 346, (2013): f794, doi:10.1136/bmj.f794.

7

Elizabeth Miller et al., “Risk of Narcolepsy in Children and Young People Receiving AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine: Retrospective Analysis,” BMJ 346, (2013): f794, doi:10.1136/bmj.f794.

8

Mayo Clinic, “Narcolepsy,” Accessed on April 13, 2023.

9

Melodie Bonvalet et al., “Autoimmunity in Narcolepsy,” Current Opinion in Pulmonary Medicine, 23, no. 6 (2017): 522-529, doi:10.1097/MCP.0000000000000426.

10

Melodie Bonvalet et al., “Autoimmunity in Narcolepsy,” Current Opinion in Pulmonary Medicine, 23, no. 6 (2017): 522-529, doi:10.1097/MCP.0000000000000426.

11

Melodie Bonvalet et al., “Autoimmunity in Narcolepsy,” Current Opinion in Pulmonary Medicine, 23, no. 6 (2017): 522-529, doi:10.1097/MCP.0000000000000426.

12

Attila Szakács, Niklas Darin and Tove Hallböök, “Increased Childhood Incidence of Narcolepsy in Western Sweden After H1N1 Influenza Vaccination,” Neurology 80, no. 14 (2013): 1315-1321, doi:10.1212/WNL.0b013e31828ab26f.

13

Attila Szakács, Niklas Darin and Tove Hallböök, “Increased Childhood Incidence of Narcolepsy in Western Sweden After H1N1 Influenza Vaccination,” Neurology 80, no. 14 (2013): 1315-1321, doi:10.1212/WNL.0b013e31828ab26f.

14

Attila Szakács, Niklas Darin and Tove Hallböök, “Increased Childhood Incidence of Narcolepsy in Western Sweden After H1N1 Influenza Vaccination,” Neurology 80, no. 14 (2013): 1315-1321, doi:10.1212/WNL.0b013e31828ab26f.

15

Markku Partinen et al., “Increased Incidence and Clinical Picture of Childhood Narcolepsy Following the 2009 H1N1 Pandemic Vaccination Campaign in Finland,” PLoS ONE 7, no. 3 (2012): e33723, doi:10.1371/journal.pone.0033723.

16

Markku Partinen et al., “Increased Incidence and Clinical Picture of Childhood Narcolepsy Following the 2009 H1N1 Pandemic Vaccination Campaign in Finland,” PLoS ONE 7, no. 3 (2012): e33723, doi:10.1371/journal.pone.0033723.

17

Carola Bardage et al., “Neurological and Autoimmune Disorders After Vaccination Against Pandemic Influenza A (H1N1) with a Monovalent Adjuvanted Vaccine: Population Based Cohort Study in Stockholm, Sweden,” BMJ 343, (2011): d5956, doi:10.1136/bmj.d5956.

18

Carola Bardage et al., “Neurological and Autoimmune Disorders After Vaccination Against Pandemic Influenza A (H1N1) with a Monovalent Adjuvanted Vaccine: Population Based Cohort Study in Stockholm, Sweden,” BMJ 343, (2011): d5956, doi:10.1136/bmj.d5956.

19

Jeff Kwong et al., “Risk of Guillain-Barré Syndrome After Seasonal Influenza Vaccination and Influenza Health-Care Encounters: A Self-Controlled Study,” The Lancet: Infectious Diseases 13, no.9: 769-776, doi:10.1016/S1473-3099(13)70104-X

20

Mayo Clinic, “Guillain-Barre syndrome,” Accessed on April 15, 2023.

21

Jeff Kwong et al., “Risk of Guillain-Barré Syndrome After Seasonal Influenza Vaccination and Influenza Health-Care Encounters: A Self-Controlled Study,” The Lancet: Infectious Diseases 13, no.9: 769-776, doi:10.1016/S1473-3099(13)70104-X.

22

Jeff Kwong et al., “Risk of Guillain-Barré Syndrome After Seasonal Influenza Vaccination and Influenza Health-Care Encounters: A Self-Controlled Study,” The Lancet: Infectious Diseases 13, no.9: 769-776, doi:10.1016/S1473-3099(13)70104-X.

23

David Juurlink, et al., “Guillain-Barré Syndrome After Influenza Vaccination in Adults: A Population-Based Study,” Journal of the American Medical Association 166, no. 20 (2006): 2217–2221, doi:10.1001/archinte.166.20.2217.

24

Jeff Kwong et al., “Risk of Guillain-Barré Syndrome After Seasonal Influenza Vaccination and Influenza Health-Care Encounters: A Self-Controlled Study,” The Lancet: Infectious Diseases 13, no.9: 769-776, doi:10.1016/S1473-3099(13)70104-X.

25

David Juurlink, et al., “Guillain-Barré Syndrome After Influenza Vaccination in Adults: A Population-Based Study,” Journal of the American Medical Association 166, no. 20 (2006): 2217–2221, doi:10.1001/archinte.166.20.2217.

26

David Juurlink, et al., “Guillain-Barré Syndrome After Influenza Vaccination in Adults: A Population-Based Study,” Journal of the American Medical Association 166, no. 20 (2006): 2217–2221, doi:10.1001/archinte.166.20.2217.

27

Tamar Lasky, et al., “The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994Influenza Vaccines,” The New England Journal of Medicine 339, no. 25 (1998): 1797-1802, doi:10.1056/NEJM199812173392501.

28

Tamar Lasky, et al., “The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994Influenza Vaccines,” The New England Journal of Medicine 339, no. 25 (1998): 1797-1802, doi:10.1056/NEJM199812173392501.

29

Matthew Wise, et al., “Guillain-Barre Syndrome During the 2009-2010 H1N1 Influenza Vaccination Campaign: Population-Based Surveillance Among 45 Million Americans,” American Journal of Epidemiology 175, no. 11 (2012): 1110–1119, doi:10.1093/aje/kws196.

30

Matthew Wise, et al., “Guillain-Barre Syndrome During the 2009-2010 H1N1 Influenza Vaccination Campaign: Population-Based Surveillance Among 45 Million Americans,” American Journal of Epidemiology 175, no. 11 (2012): 1110–1119, doi:10.1093/aje/kws196.